Related Experiment Videos
[Renaissance of thalidomide]
F Waelput1, W Feremans, M Heenen
1Institut de Pharmacie, U.L.B.
Revue Medicale De Bruxelles
|February 15, 2003
Abstract:
Thalidomide comes back forty years after the discovery of its teratogenicity. Due to its antiangiogenic and immunomodulating properties, thalidomide is proposed in the treatment of multiple myeloma but also in the management of erythema nodosus leprosis, cutaneous lupus erythematosus and severe aphtosis.